Global Bioresorbable Scaffolds Market Size, Share, Forecast Report, 2020-2027

Bioresorbable scaffolds are medical devices used during numerous surgeries, as required when one suffers from coronary artery disease; bioresorbable scaffolds are recently introduced medical devices. Major driving factors for the growth of this market are increasing prevalence of cardiovascular disease, diabetes, obesity, poor diet and lack of exercise. According to WHO (2014), cardiovascular diseases accounted for a majority of deaths globally. Moreover, number of obese population across the globe is rising continuously. In 2014, globally 39% of adults aged 18 years and above were overweight, whereas 13% were obese. Furthermore, rapid development in devices used for the cardiovascular surgeries, rising demand for bioresorbable scaffolds, adoption of desk-bound lifestyle, and government’s support for research and development of better medical devices has fuelled the market’s growth. However, availability of alternative therapies and high cost of the bioresorbable scaffolds may slower the growth of this market.

Global bioresorbable scaffolds market is expected to grow at a CAGR of 18.9% during forecasted period of 2017-2023.
Segmentation

The bioresorbable scaffolds market is segmented on the basis of material, types, application and end users. On the basis of material, the market is classified into absorbable magnesium stent (AMS), polymeric scaffold, poly carbonate scaffold and others. On the basis of types, the market is segmented into drug eluting coronary scaffolds, everolimus-eluting device, novolimus-eluting device, sirolimus-eluting device, and paclitaxel-eluting device. On the basis of application, the market is segmented into peripheral vascular intervention, regulation of blood flow and others. On the basis of end users, the market is categorised into hospitals, clinics and others.
Key Players

Some of the key player for the market are Abbott (US), Medtronic (UK), Boston Scientific Corporation (US), Biotronik (Germany), Elixir Medical Corporation (US), REVA Medical, Inc (US), Amaranth Medical, Inc. (US), Kyoto Medical Planning Co. Ltd. (Japan), Xenogenics Corporation (US), B. Braun (Germany), Cardinal Health. (US), Lombard Medical, Inc (UK), Translumina (Germany), MicroPort Scientific Corporation (China) and TERUMO CORPORATION (Japan).